Thrombolytic therapy for late thrombosis of a bioprosthetic mitral valve: atypical diagnostic echocardiographic features and a review of the literature.
Bioprosthetic valves are generally considered to carry a low risk of valve thrombosis, obviating the need for long-term anticoagulation in most patients. Few reports exist of the diagnostic characteristics and management of bioprosthetic valve thrombosis. Herein is presented a case of critical bioprosthetic mitral valve thrombosis in which successful clinical and hemodynamic resolution was achieved with intravenous thrombolysis. A current review of the bioprosthetic valve thrombosis literature is also presented.
Laksman
Zachary
Z
Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA.
Kane
Garvan C
GC
Murphy
Joseph G
JG
D000368:Aged; D001705:Bioprosthesis / Q000009:adverse effects*; D004417:Dyspnea / Q000209:etiology; D004452:Echocardiography; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006350:Heart Valve Prosthesis / Q000009:adverse effects*; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D008943:Mitral Valve / Q000000981:diagnostic imaging* / Q000601:surgery; D013300:Streptokinase / Q000627:therapeutic use; D015912:Thrombolytic Therapy; D013927:Thrombosis / Q000175:diagnosis* / Q000188:drug therapy* / Q000209:etiology
D005343:Fibrinolytic Agents; D006493:Heparin; D013300:Streptokinase